A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder.

Trial Profile

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2013

At a glance

  • Drugs Bavisant (Primary) ; Atomoxetine; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2012 Actual initiation date changed from May 2009 to Apr 2009 as reported by ClinicalTrials.gov.
    • 13 Mar 2010 Actual end date (January 2010) added as reported by ClinicalTrials.gov.
    • 13 Mar 2010 Actual patient number (430) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top